Physician profile
Sandra K Birchem
NPI 1902888241
$1,692.59
in general payments reported to CMS, 2019-2025
18 companies · $572 in 2025
The $572 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $67.43 · 2023: $343 · 2024: $710 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $236.09 | 2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $204.94 | 2023-2024 | Eliquis, Camzyos |
| Abiomed | $198.50 | 2025 | |
| Amgen INC. | $179.96 | 2022-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $156.36 | 2023-2025 | Watchman Access System, Ams 800 Artificial Urinary Sphincter |
| Abbott Laboratories | $139.41 | 2024 | Mitraclip |
| Medtronic, INC. | $123.74 | 2024-2025 | Corevalve Evolut R |
| Heartflow, INC. | $119.44 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.39 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $51.63 | 2022-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $38.21 | 2024 | |
| Scpharmaceuticals INC. | $34.12 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $27.92 | 2024 | Farxiga |
| Cvrx, INC. | $25.34 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals, LTD. | $19.54 | 2023 | Arcalyst |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $19.02 | 2025 | Amvuttra |
| Genzyme Corporation | $18.81 | 2024 | |
| Novo Nordisk INC | $17.17 | 2023 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Birchem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.